Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 1:59 AM
NCT ID:
NCT03899805
Group ID:
EG001
Title:
Leiomyosarcomas
Description:
* Participants will receive eribulin intravenously on Day 1 and Day 8
* Pembrolizumab is administered intravenously Day 1, on a 21-day cycle
Eribulin: The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
Pembrolizumab: The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
Deaths Number Affected:
12
Deaths Number At Risk:
None
Serious Number Affected:
8
Serious Number At Risk:
19
Other Number Affected:
19
Other Number At Risk:
19
Study:
NCT03899805
Results Section:
NCT03899805
Adverse Events Module:
NCT03899805